OTCMKTS:BVNRY - BAVARIAN NORDIC/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.10 0.00 (0.00 %) (As of 03/19/2019 04:00 PM ET)Previous Close$7.10Today's Range$7.0953 - $7.1652-Week Range$5.92 - $12.09Volume1,206 shsAverage Volume142 shsMarket Capitalization$688.20 millionP/E Ratio24.48Dividend YieldN/ABeta1.18 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark. Receive BVNRY News and Ratings via Email Sign-up to receive the latest news and ratings for BVNRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BVNRY Previous Symbol CUSIPN/A CIKN/A Webwww.bavarian-nordic.com Phone45-3326-8383Debt Debt-to-Equity Ratio0.17 Current Ratio6.15 Quick Ratio5.84Price-To-Earnings Trailing P/E Ratio24.48 Forward P/E Ratio-12.68 P/E GrowthN/A Sales & Book Value Annual Sales$208.06 million Price / Sales3.31 Cash Flow$0.3462 per share Price / Cash Flow20.51 Book Value$3.96 per share Price / Book1.79Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$27.54 million Net Margins-126.80% Return on Equity-19.43% Return on Assets-14.62%Miscellaneous EmployeesN/A Outstanding Shares96,930,000Market Cap$688.20 million Next Earnings Date3/25/2019 (Estimated) OptionableNot Optionable BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions What is BAVARIAN NORDIC/S's stock symbol? BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY." When is BAVARIAN NORDIC/S's next earnings date? BAVARIAN NORDIC/S is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for BAVARIAN NORDIC/S. Has BAVARIAN NORDIC/S been receiving favorable news coverage? News stories about BVNRY stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BAVARIAN NORDIC/S earned a news impact score of -1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of BAVARIAN NORDIC/S's key competitors? Some companies that are related to BAVARIAN NORDIC/S include Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Alector (ALEC), Iovance Biotherapeutics (IOVA) and Fate Therapeutics (FATE). What other stocks do shareholders of BAVARIAN NORDIC/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other BAVARIAN NORDIC/S investors own include Genmab A/S (GNMSF), Dell (DELL), Carvana (CVNA), Rent-A-Center (RCII), IQIYI (IQ), Kirkland Lake Gold (KL), DHI Group (DHX), Yext (YEXT), Cloud Peak Energy (CLD) and Canopy Growth (CGC). Who are BAVARIAN NORDIC/S's key executives? BAVARIAN NORDIC/S's management team includes the folowing people: Dr. Paul Chaplin, CEO & Pres (Age 52)Mr. Henrik Juuel, CFO & Exec. VP (Age 54)Mr. Henrik Birk, COO & Exec. VP (Age 45)Dr. Christopher R. Heery, Chief Medical OfficerDr. Tommi Kainu M.D., Ph.D., Exec. VP, Chief Bus. Officer & Member of the Exec. Management (Age 46) How do I buy shares of BAVARIAN NORDIC/S? Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BAVARIAN NORDIC/S's stock price today? One share of BVNRY stock can currently be purchased for approximately $7.10. How big of a company is BAVARIAN NORDIC/S? BAVARIAN NORDIC/S has a market capitalization of $688.20 million and generates $208.06 million in revenue each year. The company earns $27.54 million in net income (profit) each year or $0.29 on an earnings per share basis. What is BAVARIAN NORDIC/S's official website? The official website for BAVARIAN NORDIC/S is http://www.bavarian-nordic.com. How can I contact BAVARIAN NORDIC/S? BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected] MarketBeat Community Rating for BAVARIAN NORDIC/S (OTCMKTS BVNRY)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 147 (Vote Outperform)Underperform Votes: 97 (Vote Underperform)Total Votes: 244MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote "Outperform" if you believe BVNRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: How Do Front-End Loads Impact an Investment?